CN102548549A - 利用外代谢转换剂(辅酶q10)治疗肉瘤的方法 - Google Patents

利用外代谢转换剂(辅酶q10)治疗肉瘤的方法 Download PDF

Info

Publication number
CN102548549A
CN102548549A CN2010800427577A CN201080042757A CN102548549A CN 102548549 A CN102548549 A CN 102548549A CN 2010800427577 A CN2010800427577 A CN 2010800427577A CN 201080042757 A CN201080042757 A CN 201080042757A CN 102548549 A CN102548549 A CN 102548549A
Authority
CN
China
Prior art keywords
protein
sarcoma
marker
subject
expression level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800427577A
Other languages
English (en)
Chinese (zh)
Inventor
R·萨兰加拉简
N·R·纳莱恩
J·P·麦库克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytotech Labs LLC
Original Assignee
Cytotech Labs LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytotech Labs LLC filed Critical Cytotech Labs LLC
Priority to CN201711449284.2A priority Critical patent/CN108245497A/zh
Publication of CN102548549A publication Critical patent/CN102548549A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
CN2010800427577A 2009-08-25 2010-08-25 利用外代谢转换剂(辅酶q10)治疗肉瘤的方法 Pending CN102548549A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201711449284.2A CN108245497A (zh) 2009-08-25 2010-08-25 利用外代谢转换剂（辅酶q10）治疗肉瘤的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23684509P 2009-08-25 2009-08-25
US61/236,845 2009-08-25
PCT/US2010/046711 WO2011031503A2 (en) 2009-08-25 2010-08-25 Methods for treatment of a sarcoma using an epimetabolic shifter (coenzyme q10)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201711449284.2A Division CN108245497A (zh) 2009-08-25 2010-08-25 利用外代谢转换剂（辅酶q10）治疗肉瘤的方法

Publications (1)

Publication Number Publication Date
CN102548549A true CN102548549A (zh) 2012-07-04

Family

ID=43730801

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201711449284.2A Pending CN108245497A (zh) 2009-08-25 2010-08-25 利用外代谢转换剂（辅酶q10）治疗肉瘤的方法
CN2010800427577A Pending CN102548549A (zh) 2009-08-25 2010-08-25 利用外代谢转换剂(辅酶q10)治疗肉瘤的方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201711449284.2A Pending CN108245497A (zh) 2009-08-25 2010-08-25 利用外代谢转换剂（辅酶q10）治疗肉瘤的方法

Country Status (15)

Country Link
US (2) US20110064747A1 (enExample)
EP (1) EP2470169A4 (enExample)
JP (2) JP6159085B2 (enExample)
KR (1) KR101572463B1 (enExample)
CN (2) CN108245497A (enExample)
AU (2) AU2010292532A1 (enExample)
BR (1) BR112012004237A8 (enExample)
CA (1) CA2772068C (enExample)
CR (1) CR20120120A (enExample)
EA (1) EA201270325A1 (enExample)
IL (1) IL218306B (enExample)
IN (1) IN2012DN01911A (enExample)
MX (1) MX2012002208A (enExample)
SG (2) SG178547A1 (enExample)
WO (1) WO2011031503A2 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106053813A (zh) * 2016-06-25 2016-10-26 林森 一种检测鼻咽癌pdk1表达量的免疫组化试剂盒及其应用
CN106947010A (zh) * 2017-04-06 2017-07-14 哈尔滨工业大学 一种利用光引发raft聚合原位诱导自组装制备蛋白质基纳米粒子的方法
CN107001451A (zh) * 2014-07-07 2017-08-01 阿勒根公司 检测组织样品中裂解的snap25的方法
CN107226862A (zh) * 2017-05-27 2017-10-03 南京川博生物技术有限公司 特异性人ews‑fli1融合蛋白抗体的制备方法及在制备尤文肉瘤诊断抗体试剂的应用
CN110769818A (zh) * 2017-05-17 2020-02-07 博格有限责任公司 辅酶q10制剂在治疗和预防大疱性表皮松解症中的用途

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10519504B2 (en) 2009-05-11 2019-12-31 Berg Llc Methods for treatment of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
EP2694463B8 (en) 2011-04-04 2019-10-09 Berg LLC Treating central nervous system tumors with coenzyme q10
EP2906946A1 (en) 2012-10-09 2015-08-19 The Procter & Gamble Company Method of identifying or evaluating beneficial actives and compositions containing the same
EP2906197A1 (en) 2012-10-09 2015-08-19 The Procter & Gamble Company Method of identifying synergistic cosmetic combinations
US9144538B2 (en) 2013-02-08 2015-09-29 The Procter & Gamble Company Cosmetic compositions containing substituted azole and methods for alleviating the signs of photoaged skin
US9138393B2 (en) 2013-02-08 2015-09-22 The Procter & Gamble Company Cosmetic compositions containing substituted azole and methods for improving the appearance of aging skin
EA032775B1 (ru) 2013-04-08 2019-07-31 Берг Ллк Способы лечения злокачественной опухоли с использованием комбинированной терапии с коферментом q10
WO2015035094A1 (en) 2013-09-04 2015-03-12 Berg Llc Methods of treatment of cancer by continuous infusion of coenzyme q10
US10627392B2 (en) 2014-06-17 2020-04-21 Stealth Biotherapeutics Corp Methods of identifying and monitoring mitochondrial dysfunction using monocyte screening
CN105044360A (zh) * 2015-07-22 2015-11-11 浙江大学医学院附属邵逸夫医院 Rbp4作为结直肠癌血清标记物的应用及诊断试剂盒
WO2017087576A1 (en) 2015-11-16 2017-05-26 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
EP3935581A4 (en) 2019-03-04 2022-11-30 Iocurrents, Inc. DATA COMPRESSION AND COMMUNICATION USING MACHINE LEARNING
US20230080670A1 (en) * 2019-04-05 2023-03-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for treating tumors using transcription inhibition and dna damage
JP2024509196A (ja) * 2021-03-05 2024-02-29 ユニバーシティ オブ セントラル フロリダ リサーチ ファウンデーション，インコーポレイテッド 癌の治療のためのシャペロニン含有ｔｃｐ－１阻害剤

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1953743A (zh) * 2004-01-22 2007-04-25 迈阿密大学 局部辅酶q10制剂及其使用方法
US20080075722A1 (en) * 2006-02-14 2008-03-27 Depinho Ronald A Compostions, kits, and methods for identification, assessment, prevention, and therapy of cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000040749A2 (en) * 1999-01-06 2000-07-13 Genenews Inc. Method for the detection of gene transcripts in blood and uses thereof
JP2005522221A (ja) * 2002-04-17 2005-07-28 ノバルティス アクチエンゲゼルシャフト チロシンキナーゼ阻害剤に対する患者応答性の予測方法
JP2006345701A (ja) * 2003-07-01 2006-12-28 Taisho Pharmaceut Co Ltd タキサン類応答性の判別方法
US20060035981A1 (en) * 2003-08-02 2006-02-16 Mazzio Elizabeth A Inhibition of anaerobic glucose metabolism and corresponding composition as a natural non-toxic approach to cancer treatment
AU2005245572B9 (en) * 2004-05-14 2009-01-29 Ludwig Institute For Cancer Research Identification and characterization of a subset of glioblastomas sensitive to treatment with imatinib
WO2006125143A2 (en) * 2005-05-18 2006-11-23 Novartis Ag Methods for diagnosis and treatment of proliferative disorders mediated by cd40 signaling
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CN101297046B (zh) * 2005-09-02 2013-01-02 东丽株式会社 用于检测尿路上皮癌的试剂盒及方法
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
US8030013B2 (en) * 2006-04-14 2011-10-04 Mount Sinai School Of Medicine Methods and compositions for the diagnosis for early hepatocellular carcinoma
WO2009051277A1 (ja) * 2007-10-18 2009-04-23 Medical Proteoscope Co., Ltd. 手術後の予後を推定する方法及び診断キット

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1953743A (zh) * 2004-01-22 2007-04-25 迈阿密大学 局部辅酶q10制剂及其使用方法
US20080075722A1 (en) * 2006-02-14 2008-03-27 Depinho Ronald A Compostions, kits, and methods for identification, assessment, prevention, and therapy of cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
周彦梅等: "骨肉瘤新辅助化疗5例临床护理", 《齐鲁护理杂志》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107001451A (zh) * 2014-07-07 2017-08-01 阿勒根公司 检测组织样品中裂解的snap25的方法
CN106053813A (zh) * 2016-06-25 2016-10-26 林森 一种检测鼻咽癌pdk1表达量的免疫组化试剂盒及其应用
CN106947010A (zh) * 2017-04-06 2017-07-14 哈尔滨工业大学 一种利用光引发raft聚合原位诱导自组装制备蛋白质基纳米粒子的方法
CN110769818A (zh) * 2017-05-17 2020-02-07 博格有限责任公司 辅酶q10制剂在治疗和预防大疱性表皮松解症中的用途
CN107226862A (zh) * 2017-05-27 2017-10-03 南京川博生物技术有限公司 特异性人ews‑fli1融合蛋白抗体的制备方法及在制备尤文肉瘤诊断抗体试剂的应用

Also Published As

Publication number Publication date
BR112012004237A2 (pt) 2016-04-05
JP2016136938A (ja) 2016-08-04
MX2012002208A (es) 2012-06-12
EP2470169A2 (en) 2012-07-04
US20130266557A1 (en) 2013-10-10
US20110064747A1 (en) 2011-03-17
EP2470169A4 (en) 2013-03-13
JP6159085B2 (ja) 2017-07-05
BR112012004237A8 (pt) 2016-10-04
CA2772068C (en) 2017-03-21
SG178547A1 (en) 2012-03-29
CA2772068A1 (en) 2011-03-17
JP2013503175A (ja) 2013-01-31
EA201270325A1 (ru) 2012-11-30
SG10201405069QA (en) 2014-10-30
WO2011031503A2 (en) 2011-03-17
AU2016277749A1 (en) 2017-02-02
IN2012DN01911A (enExample) 2015-07-24
CR20120120A (es) 2012-07-04
KR101572463B1 (ko) 2015-11-27
WO2011031503A3 (en) 2011-07-21
CN108245497A (zh) 2018-07-06
AU2010292532A1 (en) 2012-04-05
IL218306B (en) 2018-05-31
IL218306A0 (en) 2012-04-30
KR20120050495A (ko) 2012-05-18

Similar Documents

Publication Publication Date Title
JP6159085B2 (ja) エピメタボリックシフター（コエンザイムｑ１０）を使用する肉腫の処置方法
CN102482713B (zh) 利用表观代谢转变剂、多维细胞内分子或环境影响剂诊断肿瘤障碍的方法
Herndon et al. Global transcriptome abnormalities of the eutopic endometrium from women with adenomyosis
KR20150016518A (ko) 방법
Musrap Proteomic Identification of Mediators Implicated in the Metastatic Progression of Ovarian Cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Tennessee

Applicant after: BERG PHARMA LLC

Address before: Tennessee

Applicant before: Borg Pharmaceutical Co.,Ltd.

Address after: Tennessee

Applicant after: Borg Pharmaceutical Co.,Ltd.

Address before: Tennessee

Applicant before: Berg therapeutics Ltd.

Address after: Tennessee

Applicant after: Berg therapeutics Ltd.

Address before: Tennessee

Applicant before: Cytotech Labs, LLC

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: CYTOTECH LABS LLC TO: BERG TREATMENT LLC

Free format text: CORRECT: APPLICANT; FROM: BERG TREATMENT LLC TO: BERG PHARMA LLC

Free format text: CORRECT: APPLICANT; FROM: BERG PHARMA LLC TO: BERG LLC

Free format text: CORRECT: ADDRESS; FROM:

RJ01 Rejection of invention patent application after publication

Application publication date: 20120704

RJ01 Rejection of invention patent application after publication